eFFECTOR Therapeutics, Inc. (EFTR) Key Metrics
EFTR valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $940
- Enterprise value
- −$5.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 69.6
- Price / book
- 0.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.74
EFTR key metrics, 2019–2023
Fiscal year ended December 31, 2023 · U.S. dollarsEFTR returns How much profit the business earns on the capital it uses.
Return on assets−113.2 pts
−144.3%
2023 · hover or tap a bar for each year
20192023
Asset turnover−100.0%
0.00
2023 · hover or tap a bar for each year
20192023
EFTR per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−100.0%
$0.00
2023 · hover or tap a bar for each year
20192023
Earnings per share
−$16.37
2023 · hover or tap a bar for each year
20192023
Free cash flow per share
−$13.56
2023 · hover or tap a bar for each year
20192023
Book value per share
−$2.65
2023 · hover or tap a bar for each year
20192023
Shares outstanding+32.8%
2.2M
2023 · hover or tap a bar for each year
20192023
EFTR financial health Debt, liquidity and how easily interest is covered.
Net debt+$8.2M
$2.2M
2023 · hover or tap a bar for each year
20192023
Current ratio−31.2%
0.77
2023 · hover or tap a bar for each year
20192023
Interest coverage
-11.6
2023 · hover or tap a bar for each year
20192023
Debt / assets+43.4%
1.00
2023 · hover or tap a bar for each year
20192023
EFTR efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−620 days
6,274 days
2023 · hover or tap a bar for each year
20192023
EFTR returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EFTR debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EFTR cash returned to shareholders
DividendsBuybacksFree cash flow
EFTR key metrics
2019–2023| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Per share | |||||
| Revenue per share | $0.00 | $2.16 | $0.89 | — | — |
| Earnings per share | −$16.37 | −$7.85 | $9.78 | — | — |
| Operating cash flow per share | −$13.51 | −$15.72 | −$15.40 | — | — |
| Free cash flow per share | −$13.56 | −$15.84 | −$15.43 | — | — |
| Cash per share | $8.40 | $15.97 | $30.76 | — | — |
| Book value per share | −$2.65 | $2.37 | $10.70 | — | — |
| Tangible book value per share | −$2.65 | $2.37 | $10.70 | — | — |
| Capex per share | $0.04 | $0.12 | $0.03 | — | — |
| Debt per share | $9.39 | $12.31 | $12.40 | — | — |
| Shares outstanding | 2.2M | 1.6M | 1.6M | — | — |
| Change in shares outstanding | +32.8% | +2.0% | — | — | — |
| Returns & profitability | |||||
| Return on equity (ROE) | — | −122.1% | 173.0% | — | — |
| Return on assets (ROA) | −144.3% | −31.1% | 44.7% | 130.4% | −583.7% |
| Return on tangible assets | −174.3% | −44.5% | 29.2% | 85.1% | −583.7% |
| Free cash flow margin | — | −734.3% | — | 32.6% | — |
| Income quality (OCF / net income) | — | — | −1.58 | 0.97 | — |
| Financial health | |||||
| Total debt | $20.5M | $20.3M | $20.0M | $13.0M | $15.2M |
| Cash & short-term investments | $18.4M | $26.3M | $49.7M | $15.2M | $3.4M |
| Net debt | $2.2M | −$6.0M | −$29.7M | −$2.3M | $11.8M |
| Debt / equity | — | 5.21 | 1.16 | 13.24 | — |
| Debt / assets | 1.00 | 0.70 | 0.37 | 0.78 | 2.99 |
| Net debt / EBITDA | — | — | — | −0.14 | — |
| Current ratio | 0.77 | 1.12 | 13.30 | 1.89 | 0.23 |
| Quick ratio | 0.77 | 1.12 | 13.32 | 1.89 | 0.23 |
| Interest coverage | -11.6 | -14.4 | -18.1 | 11.9 | -20.7 |
| Working capital | −$6.0M | $2.9M | $48.9M | $7.8M | −$14.7M |
| Invested capital | −$3.6M | −$2.1M | −$12.4M | −$1.3M | −$2.0M |
| Tangible asset value | −$5.8M | $3.9M | $17.3M | −$132.2M | −$13.8M |
| Net current asset value | −$6.5M | $2.8M | $16.1M | −$132.4M | −$14.7M |
| Graham number | — | — | $48.52 | — | — |
| Graham net-net per share | −$3.63 | $0.69 | $8.02 | — | — |
| Capital allocation | |||||
| Share buybacks (net) | — | — | $0 | — | $86,000 |
| Capex / revenue | — | 5.4% | 2.9% | 0.4% | — |
| Capex / operating cash flow | — | — | — | 1.1% | — |
| Capex / depreciation | 0.87 | 3.62 | 1.75 | 0.96 | 0.01 |
| Stock-based compensation / revenue | — | 150.1% | 605.6% | 1.2% | — |
| R&D / revenue | — | 656.1% | 1,395.5% | 52.0% | — |
| SG&A / revenue | — | 355.8% | 935.0% | 10.4% | — |
| Efficiency | |||||
| Days sales outstanding | — | 6.5 | 25.5 | — | — |
| Days of inventory on hand | — | -437.3 | -1,520.8 | — | — |
| Days payables outstanding | 6,274.1 | 6,893.7 | 6,562.4 | 1,077.9 | 711.0 |
| Cash conversion cycle (days) | — | -7,324.5 | -8,057.7 | — | — |
| Receivables turnover | 0.00 | 55.95 | 14.30 | — | — |
| Payables turnover | 0.06 | 0.05 | 0.06 | 0.34 | 0.51 |
| Asset turnover | 0.00 | 0.09 | 0.04 | 3.85 | 0.00 |
| Average receivables | $39,500 | $63,500 | $100,000 | — | — |
| Average payables | $1.9M | $1.0M | $431,500 | $472,500 | $598,000 |
| Average inventory | — | −$63,500 | −$100,000 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from EFTR's annual financial statements (latest annual report filed March 26, 2024) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EFTR valuation and financial ratios
It ended the year with $20.5 million of debt and $18.4 million in cash and short-term investments, net debt of $2.2 million.
See the EFTR income statement, the EFTR chart for price history, or the EFTR stock overview for the latest quote and news.
EFTR key metrics FAQ
How much debt does eFFECTOR Therapeutics have?
eFFECTOR Therapeutics had total debt of $20.5 million at the end of fiscal 2023.
What is eFFECTOR Therapeutics's current ratio?
eFFECTOR Therapeutics's current ratio was 0.77 at the end of fiscal 2023: current assets were 0.77 times current liabilities.